Researchers from the National University of Singapore and University of British Columbia have created a free online tool called the Risk of Exacerbation in Severe Asthma (RESA) e-tool to help clinicians estimate a person’s likelihood of having a serious asthma flare-up over the next 12 months. The work was recently published in The Journal of Allergy and Clinical Immunology: In Practice, entitled “Development and Validation of the Risk of Exacerbation in Severe Asthma (RESA)

Greek patients with severe asthma were found to have a notably lower asthma exacerbation rate compared with patients globally, while long-term oral corticosteroid (LTOCS) use, and importantly evidence of steroid-related disease, was substantially lower in Greece compared with Southern Europe and global rates. Differences in severe asthma characteristics, treatment patterns, and disease control between Greece, Southern Europe, and the global population have been identified in

Pathways that predict severe asthma attacks (exacerbations) were found to be similar, with matching strength of prediction, in both clinical trials (Randomised Controlled Trials, RCTs) and real-world data (RWD) settings in the new International Severe Asthma Registry (ISAR) study “Interactive Pathways of Key Prognostic Factors in Severe Asthma: A Bayesian Network Comparison of Clinical Trials & Real-World Data”. Recently published in CHEST, this study performed a novel Bayesi

Long-term oral corticosteroid (LTOCS) use has been found to be lower in Mexican patients than globally and may be associated with impact to critical health outcomes, with potentially oral corticosteroid-related diseases found to be less common in Mexican patients. These findings are reported in the real-world study, “ Severe asthma patients’ characteristics in Mexico versus International Severe Asthma Registry (ISAR) Global ” , recently published in Current Allergy and Asthma

Expanding Global Collaboration in Severe Asthma: Highlights from the ISAR Industry Symposium On 27 September 2025, the International Severe Asthma Registry (ISAR) hosted its first industry-wide symposium, welcoming representatives from multiple countries, leading pharmaceutical companies, and research organisations. This milestone event marked ISAR’s transition from a single industry funded initiative to a truly global, multi-partner collaboration. Driving Impact Through Data

The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated